{"entity":{"id":"rejuv-tx-quality-of-life","kind":"technology","name":"Quality of life after transplant and cell therapy","aka":["QoL after HSCT","return to work after transplant","psychosocial outcomes after cell therapy"],"tldr":"Most people who come through a transplant or CAR-T report, years later, a quality of life close to that of people who never had one. Underneath that, a substantial minority live with fatigue, anxiety, low mood or trouble concentrating, and the strongest predictor is having had anxiety or depression before treatment, which is treatable.","summary":"The review of late effects after blood and marrow transplantation states that transplant survivors suffer significant late effects that adversely affect morbidity, mortality, working status and quality of life, and lists neuropsychological effects alongside the organ complications. Working status appears in that sentence for a reason: return to work is one of the outcomes most affected and least studied, and it is a reasonable thing to raise with a team that is focused on counts and scans.\n\nThe best long-term patient-reported data in cell therapy come from the study of 40 patients one to five years after CD19 CAR-T described on `rejuv-tx-icans-and-neurocognition`. Mean PROMIS scores for global mental health, global physical health, social function, anxiety, depression, fatigue, pain and sleep disturbance were not clinically meaningfully different from the US general population mean. Within that, 47.5 per cent reported at least one cognitive difficulty, clinically meaningful depression or anxiety, 17.5 per cent scored at least a standard deviation below the population mean on global mental health, and 37.5 per cent reported cognitive difficulties. Younger age was associated with worse long-term global mental health, anxiety and depression, and anxiety or depression before treatment predicted the same afterwards. The authors concluded that a significant number of patients would likely benefit from mental health services.\n\nTwo things follow. The first is that group averages conceal the distribution, and a reader should not take a reassuring mean as a statement about themselves. The second is that the two strongest predictors identified, pre-existing mood disorder and younger age, point at something that can be acted on before treatment rather than discovered after it.\n\nWhat affects quality of life most after an allogeneic transplant specifically is chronic graft-versus-host disease, which is why the modified Lee Symptom Scale, a patient-reported instrument, is a key secondary endpoint in the ruxolitinib and axatilimab trials rather than an afterthought. The gap between clinician-scored and patient-reported response in REACH3, 49.7 per cent against 24.2 per cent, is the clearest single illustration in this file that organ scores and how a person feels are different measurements.\n\nWhat helps. OnCo holds records for the interventions with the best evidence in survivors generally, and they apply here: structured exercise, which is the best-evidenced single thing a survivor can do and is covered on `exercise-prescription-after-cancer`; cognitive behavioural therapy for insomnia and for persistent fatigue; and psycho-oncology services. None of these has been tested specifically in a randomised trial restricted to transplant survivors, which is why no grade is attached to this record; the evidence is borrowed from the wider survivorship literature, and the borrowing is stated rather than hidden.\n\nTwo transplant-specific additions. Chronic GvHD symptom burden responds to treating the GvHD, so persistent symptoms are a reason to review whether the GvHD is adequately controlled rather than only to offer symptomatic support. And the practical load of being a transplant survivor, long-term medication, frequent appointments, infection precautions, travel to a specialist centre, is itself a quality-of-life problem that is rarely counted as one; shared care arrangements and a written plan reduce it.","status":"established","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Quality_of_life","links":[{"label":"Ruark et al., Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy (Biol Blood Marrow Transplant 2020)","url":"https://doi.org/10.1016/j.bbmt.2019.09.037"},{"label":"Inamoto and Lee, Late effects of blood and marrow transplantation (Haematologica 2017)","url":"https://doi.org/10.3324/haematol.2016.150250"},{"label":"Zeiser et al., Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease, REACH3 (NEJM 2021)","url":"https://doi.org/10.1056/NEJMoa2033122"},{"label":"Wolff et al., Axatilimab in recurrent or refractory chronic graft-versus-host disease, AGAVE-201 (NEJM 2024)","url":"https://doi.org/10.1056/NEJMoa2401537"}],"tags":["rejuvenation","survivorship","transplant","quality-of-life","psychosocial"],"related":["rejuv-tx-icans-and-neurocognition","rejuv-tx-late-effects-overview","gvhd-chronic-overview","exercise-prescription-after-cancer","cancer-related-fatigue-management","cognitive-impairment-after-cancer-treatment","rejuv-tx-what-to-ask-for"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":["allogeneic-hsct","car-t","survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["quality-of-life","late-effects","gvhd"],"trials":[],"people":[],"bottlenecks":["b-toxicity-qol","b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Quality of life after intensive treatment is determined less by the presence of organ damage than by the combination of symptom burden, functional capacity and psychological state, which is why interventions that change none of the underlying pathology, exercise, sleep therapy and psychological treatment, move it most. Pre-treatment psychological state predicts post-treatment state because the underlying vulnerability persists through the illness rather than being created by it.","strengths":["Mean patient-reported outcomes one to five years after CAR-T were close to general population norms","The strongest predictors of poor outcome are identifiable before treatment and are treatable","Patient-reported instruments are now primary or key secondary endpoints in GvHD trials","Interventions with good evidence in survivors generally, exercise and psychological therapy, are available and inexpensive"],"limitations":["Nearly half of long-term CAR-T survivors reported at least one clinically meaningful negative neuropsychiatric outcome","The main long-term cell therapy study has 40 patients","No randomised trial of a quality-of-life intervention restricted to transplant survivors; the evidence is borrowed from wider survivorship","Return to work and financial consequences are poorly measured in this population"]},"route":"/technologies/rejuv-tx-quality-of-life/","neighbours":{"technology":[{"id":"rejuv-tx-what-to-ask-for","kind":"technology","name":"After a transplant or cell therapy: what to ask for","route":"/technologies/rejuv-tx-what-to-ask-for/"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"gvhd-chronic-overview","kind":"technology","name":"Chronic graft-versus-host disease","route":"/technologies/gvhd-chronic-overview/"},{"id":"rejuv-measure-fact-and-facit","kind":"technology","name":"FACT-G and the FACIT family: the other main questionnaire","route":"/technologies/rejuv-measure-fact-and-facit/"},{"id":"cancer-related-fatigue-management","kind":"technology","name":"Fatigue after cancer treatment: what actually works","route":"/technologies/cancer-related-fatigue-management/"},{"id":"rejuv-tx-fertility-and-growth","kind":"technology","name":"Fertility, growth and what total body irradiation costs","route":"/technologies/rejuv-tx-fertility-and-growth/"},{"id":"rejuv-tx-icans-and-neurocognition","kind":"technology","name":"ICANS, and whether thinking recovers after CAR-T","route":"/technologies/rejuv-tx-icans-and-neurocognition/"},{"id":"rejuv-tx-late-effects-overview","kind":"technology","name":"Late effects after a stem cell transplant","route":"/technologies/rejuv-tx-late-effects-overview/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"exercise-prescription-after-cancer","kind":"technology","name":"The exercise prescription after cancer: the dose the guidelines state","route":"/technologies/exercise-prescription-after-cancer/"},{"id":"cognitive-impairment-after-cancer-treatment","kind":"technology","name":"Thinking and memory after cancer treatment: what is measurable, and what helps","route":"/technologies/cognitive-impairment-after-cancer-treatment/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"term":[{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"}],"bottleneck":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"trial":[{"id":"rejuv-trial-allocare","kind":"trial","name":"AlloCare: a stepped-care late-effects service after allogeneic transplant","route":"/trials/rejuv-trial-allocare/"}]}}